County consultants flag GLP‑1 weight‑loss drugs as major cost driver; propose importation vendor and provider contracts

County benefit consultants presented a health‑fund trend analysis showing medical and pharmacy claims rising year‑to‑date and projecting FY2026 medical claims at about $23.3 million and FY2027 near $28.9 million. The consultants identified GLP‑1 and related weight‑loss drugs as a leading driver of pharmacy costs and said six drugs account for a substantial portion of pharmacy spending.

The firm's presenter said a personal importation program through a selected vendor (VeracityRx) could produce savings of about $1,493,000 for the six GLP‑1 drugs based on October–June numbers; the consultants also recommended soliciting proposals for medical, pharmacy and stop‑loss services and exploring direct provider contracts or local weight‑management programs to reduce per‑employee monthly costs. "Potential savings for those 6 GLP‑one drugs including those weight loss drugs, is $1,490,000," the consultant stated. Commissioners discussed program design, formulary changes, and how to exclude or modify coverage for GLP‑1 drugs while offering alternatives through structured programs. The court acknowledged the presentation and directed staff to proceed with RFPs and further analysis.